Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts.
Journal: Annals of the rheumatic diseases
Published: August 02, 2025
Dexamethasone Suppression Testing in a Contemporary Cohort with Adrenal Incidentalomas in Two U.S. Integrated Healthcare Systems.
Journal: Biomedicines
Published: November 03, 2023
Current Challenges and Perspectives on Developing a Clinical Trial Design for ADPKD.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: August 23, 2022
Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design.
Journal: Kidney international reports
Published: April 12, 2021
A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD.
Journal: Kidney international reports
Published: October 15, 2019
The NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations.
Journal: Kidney international reports
Published: October 15, 2019
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: February 05, 2018
Tolvaptan in Later-Stage Polycystic Kidney Disease.
Journal: The New England journal of medicine
Published: February 01, 2018
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Journal: The New England journal of medicine
Published: November 07, 2017
Last Updated: 09/26/2026